JP2010528013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528013A5 JP2010528013A5 JP2010509385A JP2010509385A JP2010528013A5 JP 2010528013 A5 JP2010528013 A5 JP 2010528013A5 JP 2010509385 A JP2010509385 A JP 2010509385A JP 2010509385 A JP2010509385 A JP 2010509385A JP 2010528013 A5 JP2010528013 A5 JP 2010528013A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administered
- composition according
- interferon
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 108010050904 Interferons Proteins 0.000 claims 6
- 102000014150 Interferons Human genes 0.000 claims 6
- 229940079322 interferon Drugs 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 3
- 229960000329 ribavirin Drugs 0.000 claims 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 3
- 238000011269 treatment regimen Methods 0.000 claims 3
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 238000011285 therapeutic regimen Methods 0.000 claims 2
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims 1
- 229940122280 Cytochrome P450 inhibitor Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93110807P | 2007-05-21 | 2007-05-21 | |
| US99443007P | 2007-09-19 | 2007-09-19 | |
| PCT/US2008/006572 WO2008144072A1 (en) | 2007-05-21 | 2008-05-21 | Dose forms comprising vx- 950 and their dosage regimen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014034070A Division JP2014132015A (ja) | 2007-05-21 | 2014-02-25 | Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010528013A JP2010528013A (ja) | 2010-08-19 |
| JP2010528013A5 true JP2010528013A5 (enExample) | 2011-07-07 |
Family
ID=39597267
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010509385A Pending JP2010528013A (ja) | 2007-05-21 | 2008-05-21 | Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン |
| JP2014034070A Pending JP2014132015A (ja) | 2007-05-21 | 2014-02-25 | Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014034070A Pending JP2014132015A (ja) | 2007-05-21 | 2014-02-25 | Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100189688A1 (enExample) |
| EP (1) | EP2157974A1 (enExample) |
| JP (2) | JP2010528013A (enExample) |
| CN (1) | CN101854936A (enExample) |
| AU (1) | AU2008254435A1 (enExample) |
| CA (1) | CA2688554A1 (enExample) |
| MX (1) | MX2009012598A (enExample) |
| WO (1) | WO2008144072A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| CA2738477A1 (en) * | 2008-09-24 | 2010-04-01 | Robert S. Kauffman | Therapeutic regimen comprising peg-interferon, ribavirin and vx-950 for the treatment of hepatitis |
| EP2358439A1 (en) * | 2008-11-05 | 2011-08-24 | Vertex Pharmaceuticals Incorporated | Methods for treating hepatitis c virus infection |
| JP2012517478A (ja) * | 2009-02-12 | 2012-08-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤 |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| WO2011094489A1 (en) | 2010-01-29 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Therapies for treating hepatitis c virus infection |
| WO2011156545A1 (en) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Viral dynamic model for hcv combination therapy |
| TW201208704A (en) | 2010-07-14 | 2012-03-01 | Vertex Pharma | Palatable pharmaceutical composition |
| DE202012012956U1 (de) | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| WO2013116339A1 (en) | 2012-01-31 | 2013-08-08 | Vertex Pharmaceuticals Incorporated | High potency formulations of vx-950 |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY141025A (en) * | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
-
2008
- 2008-05-21 CN CN200880025665A patent/CN101854936A/zh active Pending
- 2008-05-21 MX MX2009012598A patent/MX2009012598A/es not_active Application Discontinuation
- 2008-05-21 EP EP08754666A patent/EP2157974A1/en not_active Withdrawn
- 2008-05-21 CA CA2688554A patent/CA2688554A1/en not_active Abandoned
- 2008-05-21 WO PCT/US2008/006572 patent/WO2008144072A1/en not_active Ceased
- 2008-05-21 JP JP2010509385A patent/JP2010528013A/ja active Pending
- 2008-05-21 AU AU2008254435A patent/AU2008254435A1/en not_active Abandoned
-
2009
- 2009-11-20 US US12/592,225 patent/US20100189688A1/en not_active Abandoned
-
2014
- 2014-02-25 JP JP2014034070A patent/JP2014132015A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010528013A5 (enExample) | ||
| JP2008518943A5 (enExample) | ||
| Li et al. | Current therapy for chronic hepatitis C: The role of direct-acting antivirals | |
| HRP20110169T1 (hr) | Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c | |
| JP2011519364A5 (enExample) | ||
| Dore | The changing therapeutic landscape for hepatitis C. | |
| JP2007522237A5 (enExample) | ||
| JP2013529627A5 (enExample) | ||
| BRPI0811020A2 (pt) | Composto, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática, de intensificação da função hepática em indivíduo com infecção do vírus da hepatite c e métodos de síntese de compostos, de administração de inibidor da infecção do vírus da hepatite c (hcv) e de distribuição de forma de dosagem oral. | |
| JP2007509950A5 (enExample) | ||
| JP2012517478A5 (enExample) | ||
| RU2012136824A (ru) | Способы лечения вирусной инфекции гепатита с | |
| CA2573207A1 (en) | Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv) | |
| BRPI0811447A2 (pt) | Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c. | |
| EP2368900A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| RU2007119725A (ru) | Лекарственные формы | |
| RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| WO2006130553A3 (en) | Hcv protease inhibitors | |
| WO2006016930A3 (en) | Methods for treating hcv infection | |
| WO2011009961A1 (en) | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis | |
| CL2011000571A1 (es) | Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma. | |
| JP2013518124A5 (enExample) | ||
| WO2008024843A2 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
| RU2010153688A (ru) | Режим дозирования телапревира | |
| US20140135259A1 (en) | Treatment of hepatitis c virus |